Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015

Vaccine

Volumn 35, Issue 43, 2017, Pages 5799-5807

  Puig Barbera J ^a,b   Mira Iglesias, A ^a   Tortajada Girbes M ^c   Lopez Labrador F X ^a,d   Librero Lopez J ^e,f   Diez Domingo J ^a   Carballido Fernandez M ^g,h   Carratala Munuera C ^i,j   Correcher Medina, P ^k   Gil Guillen V ^l   Limon Ramirez R ^m   Mollar Maseres, J ⁿ   Otero Reigada, M C ⁿ   Schwarz, H ^o  

^a Fundación FISABIO Salud Pública   (Spain)

^b Centro de Salud Publica de Castellon   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e Red de Investigación en Servicios de Salud en Enfermedades Crónicas   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g Faculty of Medicine   (Spain)

^h HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁱ MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^j HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^k HOSPITAL LLUÍS ALCANYÍS   (Spain)

^l Hospital de Elda   (Spain)

^m HOSPITAL DE LA PLANA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

more..

Author keywords

Influenza vaccine; Vaccine effectiveness; Waning protection

Indexed keywords

INFLUENZA VACCINE; VACUNA ANTIGRIPAL PASTEUR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; SEASONAL VARIATION; SENSITIVITY ANALYSIS; VERY ELDERLY; VIRUS STRAIN; ADOLESCENT; HOSPITALIZATION; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); PROCEDURES; SEASON; TIME FACTOR; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEASONS; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 85029573102     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.09.035     Document Type: Article

References (40)

1. World Health Organization, Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec 87 (2012), 461–476.
2. Monto, A.S., Ansaldi, F., Aspinall, R., McElhaney, J.E., Montaño, L.F., Nichol, K.L., et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 27 (2009), 5043–5053.
3. Osterholm, M.T., Kelley, N.S., Sommer, A., Belongia, E.A., Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2011), 36–44.
4. Skowronski, D.M., Tweed, S.A., De Serres, G., Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?. J Infect Dis 197 (2008), 490–502.
5. Ambrose, C.S., Wu, X., Belshe, R.B., The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 29 (2010), 806–811.
6. Petrie, J.G., Ohmit, S.E., Truscon, R., Johnson, E., Braun, T.M., Levine, M.Z., et al. Modest waning of influenza vaccine efficacy and antibody titers during the 2007–2008 influenza season. J Infect Dis 214 (2016), 1142–1149.
7. Kissling, E., Valenciano, M., Larrauri, A., Oroszi, B., Cohen, J., Nunes, B., et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill, 18, 2013 pii=20390.
8. Castilla, J., Martinez-Baz, I., Martinez-Artola, V., Reina, G., Pozo, F., Garcia Cenoz, M., et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill, 18, 2013:pii:20388.
9. Pebody, R., Andrews, N., McMenamin, J., Durnall, H., Ellis, J., Thompson, C., et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill, 18, 2013 pii: 20389.
10. Sullivan, S.G., Komadina, N., Grant, K., Jelley, L., Papadakis, G., Kelly, H., Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. J Med Virol 86 (2014), 1017–1025.
11. Andrews, N., McMenamin, J., Durnall, H., Ellis, J., Lackenby, A., Robertson, C., et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill 19 (2014), 5–13.
12. Kissling, E., Nunes, B., Robertson, C., Valenciano, M., Reuss, A., Larrauri, A., et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?. Euro Surveill, 21, 2016.
13. Ferdinands, J.M., Fry, A.M., Reynolds, S., Petrie, J., Flannery, B., Jackson, M.L., Belongia, E.A., Intraseason waning of influenza vaccine protection: evidence from the US influenza vaccine effectiveness network, 2011–12 through 2014–15. Clin Infect Dis, 2016, 10.1093/cid/ciw816 pii: ciw816 [Epub ahead of print].
14. Rothman, K.J., Greenland, S., Lash, T.L., Validity in epidemiological studies. Modern epidemiology. Philadelphia: Wolters Kluwer Health/Lippincott, 2008, Williams & Wilkins, 128–147.
15. Wolkewitz, M., Beyersmann, J., Gastmeier, P., Schumacher, M., Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling. Methods Inf Med 48 (2009), 438–443.
16. Puig-Barberà, J., García-de-Lomas, J., Díez-Domingo, J., Arnedo-Pena, A., Ruiz-García, M., Limón-Ramírez, R., et al. Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011–2012 A(H3N2) predominant influenza season, Valencia, Spain. PLoS One, 9, 2014, e112294.
17. Pearce, N., What does the odds ratio estimate in a case-control study?. Int J Epidemiol 22 (1993), 1189–1192.
18. López-Labrador, F.X., Natividad-Sancho, A., Pisareva, M., Komissarov, A., Salvatierra, K., Fadeev, A., et al. Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season. J Clin Virol 84 (2016), 32–38.
19. Puig-Barberà, J., Natividad-Sancho, A., Calabuig-Pérez, J., Lluch-Rodrigo, J.A., Pastor-Villalba, E., Martínez-Úbeda, S., Díez-Domingo, J., Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011–2012 influenza season: a comparative effectiveness study using the Valencia health care information system. Vaccine 32 (2014), 5447–5454.
20. Kirkwood BR, Sterne JAC. Analysis of clustered data. In: Essential medical statistics. Malden, Mass.: Blackwell Science; 2003. p. 355–370.
21. Motulsky, H.C.A., Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting. 2004, Oxford University Press, Oxford; New York.
22. Karim, M.E., Gustafson, P., Petkau, J., Tremlett, H., Long-term benefits and adverse effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epidemiol 184 (2016), 325–335.
23. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
24. McCauley J, Daniels R, Lin YP, Zheng X, Gregory V, Whittaker L, et al. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 20-22 Feb 2012. The Francis Crick Institute. WHO Collaborating Centre for Reference and Research on Influenza National Institute for Medical Research, London; February 2012. Available: https://www.crick.ac.uk/media/221907/interim-report-feb-2012.pdf.
25. McCauley J, Daniels R, Lin YP, Zheng X, Gregory V, Whittaker L, et al. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 2015/16. The Francis Crick Institute. WHO Collaborating Centre for Reference and Research on Influenza National Institute for Medical Research, London; February 2015. Available: https://www.crick.ac.uk/media/221813/nimr-report-feb2015-web.pdf.
26. World Health Organization, Review of the 2011–2012 winter influenza season, northern hemisphere. Wkly Epidemiol Rec 87 (2012), 233–240.
27. World Health Organization, Review of the 2014–2015 influenza season in the northern hemisphere. Wkly Epidemiol Rec 90 (2015), 281–296.
28. Jiménez-Jorge, S., de Mateo, S., Delgado-Sanz, C., Pozo, F., Casas, I., Garcia-Cenoz, M., et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination. BMC Infect Dis, 13, 2013, 441.
29. Radin, J.M., Hawksworth, A.W., Myers, C.A., Ricketts, M.N., Hansen, E.A., Brice, G.T., Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010–2011 through 2013–2014. Vaccine 34 (2016), 3907–3912.
30. Durham, L.K., Longini, I.M., Halloran, M.E., Clemens, J.D., Nizam, A., Rao, M., Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Am J Epidemiol 147 (1998), 948–959.
31. Ellis, Paul D., The essential guide to effect sizes: statistical power, meta-analysis, and the interpretation of research results. 2010, Cambridge University Press, Cambridge; New York.
32. Foppa, I.M., Haber, M., Ferdinands, J.M., Shay, D.K., The case test-negative design for studies of the effectiveness of seasonal influenza vaccine. Vaccine 31 (2013), 3104–3109.
33. Smith, D.J., Forrest, S., Ackley, D.H., Perelson, A.S., Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A 96 (1999), 14001–14006.
34. Hensley, S.E., Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. Curr Opin Virol 8 (2014), 85–89.
35. Belongia, E.A., Sundaram, M.E., McClure, D.L., Meece, J.K., Ferdinands, J., VanWormer, J.J., Waning vaccine protection against influenza A(H3N2) illness in children and older adults during a single season. Vaccine 33 (2015), 246–251.
36. Puig-Barberà, J., Díez-Domingo, J., Arnedo-Pena, A., Ruiz-García, M., Pérez-Vilar, S., Micó-Esparza, J.L., et al. Effectiveness of the 2010–2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. Vaccine 30 (2012), 5714–5720.
37. Puig-Barberà, J., Natividad-Sancho, A., Calabuig-Pérez, J., Lluch-Rodrigo, J.A., Pastor-Villalba, E., Martínez-Úbeda, S., et al. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine 31 (2013), 3995–4002.
38. De Serres, G., Skowronski, D.M., Ambrose, C., The test-negativee design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical. Eurosurveillance, 18, 2013:pii=20585.
39. Foppa, I.M., Ferdinands, J.M., Chaves, S.S., Haber, M.J., Reynolds, S.B., Flannery, B., Fry, A.M., The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings. Int J Epidemiol, 2016:pii: dyw022. [Epub ahead of print].
40. Halloran, M.E., Longini, I.M., Struchiner, C.J., Design and interpretation of vaccine field studies. Epidemiol Rev 21 (1999), 73–88.